Black Diamond Therapeutics (NASDAQ:BDTX) Announces Quarterly Earnings Results

Black Diamond Therapeutics (NASDAQ:BDTX) announced its earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.09, Zacks reports.

Black Diamond Therapeutics Stock Down 1.2 %

Shares of BDTX traded down $0.04 during mid-day trading on Wednesday, hitting $3.21. 161,167 shares of the company traded hands, compared to its average volume of 820,270. The business has a 50 day moving average of $4.27 and a 200 day moving average of $5.04. The company has a market capitalization of $181.40 million, a PE ratio of -2.17 and a beta of 2.51. Black Diamond Therapeutics has a 1-year low of $1.62 and a 1-year high of $7.66.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Piper Sandler raised their price objective on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. Raymond James began coverage on Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price for the company. Wedbush reissued an “outperform” rating and set a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.